Epidural Hematoma Risks Associated With Ceasing Versus Maintaining Anticoagulant and/or Antiplatelet Medications for Spine Facet Interventions
- PMID: 40570143
- DOI: 10.1097/PHM.0000000000002795
Epidural Hematoma Risks Associated With Ceasing Versus Maintaining Anticoagulant and/or Antiplatelet Medications for Spine Facet Interventions
Abstract
Background: Facet joint interventions are commonly performed procedures in patients with neck and back pain, including patients managed with anticoagulant/antiplatelet medications. Temporary cessation of anticoagulant/antiplatelet medications may increase the risk of thromboembolic complications, which may be unnecessary.
Objective: The aim of the study was to determine the risk of clinically relevant hemorrhagic complications in patients undergoing facet interventions.
Methods: Consecutive patients from September 19, 2009, to June 16, 2017, who were on anticoagulant/antiplatelet medication medications and scheduled for an any facet intervention in the cervical, thoracic, and lumbosacral spine were retrospectively audited for bleeding complications for a minimum of 90 days after procedure.
Results: Five hundred eighty-two procedures targeting the cervical, thoracic, or lumbosacral facet joints were performed on patients on anticoagulant or antiplatelet medications. One hundred twenty-eight patients ceased their anticoagulant/antiplatelet medications before the procedure and 454 maintained anticoagulant/antiplatelet medications. No clinically relevant epidural hematomas were noted in the patient cohort (0/582, 0%, 95% confidence interval = 0.0%-0.6%).
Discussion/conclusions: The risk of clinically relevant bleeding complications including epidural hematoma in properly performed facet interventions is low. This information is crucial in being able to quantitatively determine the risk of ceasing or maintaining anticoagulant/antiplatelet medications before cervical thoracic and lumbar facet interventions.
Keywords: Anticoagulant; Facet Intervention; Medial Branch Blocks.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article.
References
-
- Carr CM, Plastaras CT, Pingree MJ, et al.: Immediate adverse events in interventional pain procedures: a multi-institutional study. Pain Med 2016;17:2155–61
-
- Grymonprez M, Simoens C, Steurbaut S, et al.: Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace 2022;24:887–98
-
- Navar AM, Kolkailah AA, Overton R, et al.: Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J Am Heart Assoc 2022;11:e026723
-
- Goodman BS, House LM, Vallabhaneni S, et al.: Anticoagulant and antiplatelet management for spinal procedures: a prospective, descriptive study and interpretation of guidelines. Pain Med 2017;187:1218–24
-
- Narouze S, Benzon HT, Provenzano D, et al.: Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (SECOND EDITIOn): guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 2018;43:225–62
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
